Maricann Group (CNSX:MARI – Get Free Report) has been given a $7.50 target price by equities research analysts at National Bankshares in a research report issued on Thursday,BayStreet.CA reports. The firm presently has an “outperform” rating on the stock.
Separately, BMO Capital Markets upped their price objective on shares of Maricann Group from $5.50 to $5.75 in a research note on Friday, November 29th.
Read Our Latest Research Report on MARI
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Read More
- Five stocks we like better than Maricann Group
- Market Cap Calculator: How to Calculate Market Cap
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- How to Plot Fibonacci Price Inflection Levels
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Investing in the High PE Growth Stocks
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
